| Trial ID: | L5531 |
| Source ID: | NCT00434499
|
| Associated Drug: |
Egcg
|
| Title: |
Effect of EGCG on the Body's Response to Insulin
|
| Acronym: |
|
| Status: |
WITHDRAWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Hypertension|Obesity|Type 2 Diabetes|Insulin Resistance
|
| Interventions: |
DRUG: EGCG
|
| Outcome Measures: |
Primary: Improvement in insulin resistance, measurements of insulin resistance prior to study drug, after 4 weeks of EGCG or placebo and at end of study, 14 weeks | Secondary: Improvement in endothelial dysfunction, measurements of endothelial function prior to study drug, after 4 weeks of EGCG or placebo and at end of study, 14 weeks
|
| Sponsor/Collaborators: |
Sponsor: University of Maryland, Baltimore
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
0
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: CROSSOVER|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2007-02
|
| Completion Date: |
2015-12
|
| Results First Posted: |
|
| Last Update Posted: |
2022-03-04
|
| Locations: |
University of Maryland, Baltimore, Maryland, 21201, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT00434499
|
